Compare Meta Platforms Inc (META) vs Pfizer Inc (PFE) Price & Performance

META stock trades at $646.96, up 0.15% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong earnings beats in recent quarters, including Q1 2026 EPS of $10.44 versus $6.70 expected, driven by robust revenue growth and a net income margin of 32.84%. Recent developments include the launch of the Muse Spark AI model and a dividend payment scheduled for June 2026.

The outlook remains positive with analyst consensus pointing to a $817.32 price target and 79% buy ratings. Key opportunities include AI innovation and revenue expansion, while risks involve regulatory lawsuits and high capital expenditures. The stock's valuation at a P/E of 23.49 appears reasonable given growth prospects, but investors should monitor legal and competitive pressures.

Pfizer (PFE) trades at $25.05, down 0.36% on the day, with a bullish technical signal supported by strong quarterly earnings beats. The company maintains solid profitability with a 73.51% gross margin and 11.83% net income margin, though revenue has moderated post-pandemic. Recent news highlights pipeline advancements in oncology and obesity treatments, positioning PFE for potential growth catalysts in 2026.

The outlook for Pfizer is cautiously optimistic, with a consensus price target of $28.25 offering 13% upside. Key opportunities include dividend stability and pipeline innovation, while risks involve patent cliffs and competitive pressures. Analyst sentiment is mixed with 38% buy ratings, reflecting balanced views on recovery potential versus near-term challenges.